CertaraCERT
About: Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
Employees: 1,391
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
32% more call options, than puts
Call options by funds: $310K | Put options by funds: $235K
24% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 38
4% more funds holding
Funds holding: 216 [Q2] → 225 (+9) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
3.2% less ownership
Funds ownership: 75.14% [Q2] → 71.94% (-3.2%) [Q3]
19% less capital invested
Capital invested by funds: $1.67B [Q2] → $1.35B (-$319M) [Q3]
30% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 88
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Barclays Luke Sergott 27% 1-year accuracy 13 / 48 met price target | 12%upside $12 | Equal-Weight Maintained | 7 Nov 2024 |
Baird Joe Vruwink 50% 1-year accuracy 21 / 42 met price target | 21%upside $13 | Neutral Maintained | 5 Nov 2024 |
UBS Dan Leonard 29% 1-year accuracy 2 / 7 met price target | 49%upside $16 | Buy Upgraded | 27 Sept 2024 |
Financial journalist opinion
